**Supplementary Table 1** Blood and cerebrospinal fluid analyses

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **Day 1** | **Day 4** | **Day 8** | **Cut-offs** |
| **Blood analyses** | | | | |
| WBC, x103/uL | 6.3 | 12.24 | 9.37 | 4.00-10.80 |
| Neutrophils, x103/uL | 4.37 | 11.37 | 6.55 | 1.50-8.00 |
| Lymphocytes, x103/uL | 1.03 | 0.54 | 1.79 | 0.90-4.00 |
| Hb, mg/dL | 15.4 | 15 | 14.6 | 14.00-18.00 |
| PLT, x103/uL | 195 | 313 | 297 | 130-400 |
| CRP, mg/L | 2.8 | 0.9 | 0.4 | 5 |
| Fibrinogen mg/dL | 340 | 213 | 213 | 170-410 |
| D-Dimer, ng/mL | 968 | 759 | 895 | < 232 |
| Ferritin, mg/dL | 123 | 155 | 198 | 200-350 |
| **CSF analyses** | | | | |
| Cell count/uL, n | 19 | 19 | 38 | <4 |
| Of which, % lymphocytes | 77 | 85 | - |  |
| Protein, mg/dL | 69.6 | 127.2 | 91.4 | 15-45 |
| Glucose, mg/dL | 58 | 88 | 47 | 50-100 |
| SARS-CoV-2 RNA | Neg | Neg | - | Negative |
| Link index | - | 0.5 | 0.5 | 0.1-0.7 |
| Oligoclonal bands | - | Neg | - | Negative |
| IL-6, pg/mL | - | 2.36 | 2.59 | <1.30 |
| IL-8, pg/mL | - | >1100 | 97 | <72 |
| TNF-α, pg/mL | - | 1.31 | 0.28 | <0.2 |
| β2M, mg/L | - | 3.06 | 3.88 | <1.8 |
| Tau, pg/mL | - | 231 | 441 | <479 |
| NfL, pg/mL | - | 975 | 807 | <1850 |

**Abbreviations:** WBC, white blood cells; Hb, hemoglobin; PLT, platelets; CRP, C-reactive protein; CSF, cerebrospinal fluid; interleukin 6, IL-6; interleukin 8, IL-8; TNF-α, tumor necrosis factor alpha; β2M, β2-microglobulin; NfL, neurofilament light.

Immunological screening included antibodies against ENA, ANA, ANCA, NMDAR, LGI1, CASPR2, GABAAR, GABABR and AMPAR, Ri, Yo, Ma2, Hu, Amphiphysin, Complement, Typhoid function and autoimmunity (anti-thyroglobulin, anti-thyroid peroxidase), IgM and IgG for Borrelia Burgdorferi. CSF viral screening included HSV-1, HSV-2, HSV-6, HSV-8, Epstein-Barr Virus, Varicella-zooster virus (human alpha herpesvirus 3, HHV-3), adenovirus and enterovirus)

CSF samples were analyzed at the Clinical Neurochemistry Laboratory at Sahlgrenska University Hospital (Mölndal, Sweden). CSF concentrations of IL-6, IL-8 and TNF-α were measured using a Mesoscale Discovery (MSD) multiplexed immunoassay (MSD, Rockville, MD). CSF β2M concentration was measured by nephelometry on a BNProSpec instrument (Dade Behring, Deerfield, IL), CSF tau concentration was measured by Lumipulse (Fujirebio, Ghent, Belgium). CSF NfL concentration was measured using an in house enzyme-linked immunosorbent assay (Gaetani L et al., Alzheimers Res Ther. 2018 Jan 23;10(1):8). All analyses were performed by board-certified laboratory technicians who were blinded to clinical data.